Top Markets
#1 DogBull DogBull +108.80%
#2 MarsCoin MarsCoin +74.07%
#3 Siacoin Siacoin +56.02%
#4 ADO Protocol ADO Protocol +52.76%
#5 The Bitcoin Bull The Bitcoin Bull +26.51%
#6 Ontology Gas Ontology Gas +22.36%
#7 Useless Coin Useless Coin +16.23%
#8 Apertum Apertum +15.00%
#9 Uniswap Uniswap +13.46%
#10 Arowana Arowana +12.91%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Hansa Biopharma AB Hansa Biopharma AB

Hansa Biopharma AB

HNSBF
Rank in Stocks #15161
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development... Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Share Price
$3.70
Last synced: 2026-08-28
Market Cap
$369.01M
Change (1 day)
0.00%
Change (1 year)
35.04%
Country
SE
Trade Hansa Biopharma AB (HNSBF)

Category

Healthcare
P/E ratio for Hansa Biopharma AB (HNSBF)
P/E ratio as of 2026 TTM: 0
According to Hansa Biopharma AB latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Hansa Biopharma AB from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 25.48 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 217.98 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.